Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Condition:   Stage III Non-small Cell Lung Cancer Interventions:   Drug: Toripalimab;   Drug: JS004;   Drug: Pemetrexed;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Procedure: Surgery Sponsor:   Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials